627 related articles for article (PubMed ID: 29569184)
1. Mucosal Melanoma: a Literature Review.
Yde SS; Sjoegren P; Heje M; Stolle LB
Curr Oncol Rep; 2018 Mar; 20(3):28. PubMed ID: 29569184
[TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
4. Melanoma and Immune Checkpoint Inhibitors.
Furue M; Ito T; Wada N; Wada M; Kadono T; Uchi H
Curr Oncol Rep; 2018 Mar; 20(3):29. PubMed ID: 29569208
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
6. (Neo)adjuvant systemic therapy for melanoma.
van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
[TBL] [Abstract][Full Text] [Related]
7. [Not Available].
Pagès C; Baroudjian B; Lebbé C
Bull Cancer; 2016 Nov; 103 Suppl 1():S132-S137. PubMed ID: 28057176
[TBL] [Abstract][Full Text] [Related]
8. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
[TBL] [Abstract][Full Text] [Related]
9. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
10. Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors.
Papaspyrou G; Garbe C; Schadendorf D; Werner JA; Hauschild A; Egberts F
Melanoma Res; 2011 Dec; 21(6):475-82. PubMed ID: 21897303
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
13. Melanoma Immunotherapy in the Elderly.
Orloff M
Curr Oncol Rep; 2018 Mar; 20(2):20. PubMed ID: 29500787
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
15. Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck.
Thierauf J; Veit JA; Affolter A; Bergmann C; Grünow J; Laban S; Lennerz JK; Grünmüller L; Mauch C; Plinkert PK; Hess J; Hoffmann TK
Melanoma Res; 2015 Dec; 25(6):503-9. PubMed ID: 26352784
[TBL] [Abstract][Full Text] [Related]
16. Single versus combination immunotherapy drug treatment in melanoma.
Grimaldi AM; Marincola FM; Ascierto PA
Expert Opin Biol Ther; 2016; 16(4):433-41. PubMed ID: 26642234
[TBL] [Abstract][Full Text] [Related]
17. Mucosal melanoma of the head and neck: a systematic review of the literature.
Lazarev S; Gupta V; Hu K; Harrison LB; Bakst R
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1108-18. PubMed ID: 25539369
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of melanoma.
Kee D; McArthur G
Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
[TBL] [Abstract][Full Text] [Related]
19. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better.
Atrash S; Makhoul I; Mizell JS; Hutchins L; Mahmoud F
J Oncol Pharm Pract; 2017 Apr; 23(3):215-219. PubMed ID: 26811403
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint inhibition for advanced mucosal melanoma.
Thierauf J; Veit JA; Hess J; Treiber N; Lisson C; Weissinger SE; Bommer M; Hoffmann TK
Eur J Dermatol; 2017 Apr; 27(2):160-165. PubMed ID: 28174141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
